Figure 6.
Figure 6. Tr cells generated with DCVIPs prevent acute GVHD. DCs were generated from mouse BM cells in the absence (DCcontrols) or presence (DCVIPs) of VIP and activated with LPS to induce DC maturation. CD4 and CD8 T cells (H-2b) were exposed to allogeneic (H-2d)DCcontrols or DCVIPs to generate potential Tr cells (Trcontrols and TrVIPs). (A) Balb/c mice (H-2d) received transplants of T-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from B6 (H-2b) mice (left panel) and B6 mice (H-2b) received transplants of T cell-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from Balb/c (H-2d) mice (right panel). Medium (untreated, •), CD4Trcontrols (○) or CD4TrVIPs (▾) (H-2b) were injected (1.5 × 106 cells/mouse) in both recipients 2 days after allogeneic transplantation, and survival was monitored (10 animals/group). *P < .01 versus untreated recipients. (B) The effect of CD4TrVIPs is dose-dependent. Balb/c mice (H-2d) received transplants of T-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from B6 (H-2b) mice and CD4TrVIPs (H-2b) were injected in recipients together with transplantation at different numbers: 1.5 × 106 cells, BMS/TrVIPs ratio of 10:1 (○); 3 × 105 cells, BMS/TrVIPs ratio 50:1 (▾); or 1.5 × 105 cells, BMS/TrVIPs ratio 100:1 (▿). Untreated control mice (•, n = 10). *P < .01 versus untreated recipients. (C) Balb/c mice that were (•) or that had received injections of CD4TrVIPs and been treated with control immunoglobulin (○), anti-IL-10 (▾), anti-TGF-β (▿), or anti-IL-10 plus anti-TGFβ (▪) antibodies after BMS B6 transplantation (n = 10). *P < .01 versus control immunoglobulin-treated CD4TrVIPs recipients. (D) Balb/c mice (H-2d) were given transplants of T cell-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from B6 (H-2b) mice. Recipients were treated with medium (untreated, •), CD8Trcontrols (○) or CD8TrVIPs (▾) (5 × 106 cells) at time of allogeneic transplantation and survival was monitored (5 animals/group). *P < .01 versus untreated recipients.

Tr cells generated with DCVIPs prevent acute GVHD. DCs were generated from mouse BM cells in the absence (DCcontrols) or presence (DCVIPs) of VIP and activated with LPS to induce DC maturation. CD4 and CD8 T cells (H-2b) were exposed to allogeneic (H-2d)DCcontrols or DCVIPs to generate potential Tr cells (Trcontrols and TrVIPs). (A) Balb/c mice (H-2d) received transplants of T-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from B6 (H-2b) mice (left panel) and B6 mice (H-2b) received transplants of T cell-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from Balb/c (H-2d) mice (right panel). Medium (untreated, •), CD4Trcontrols (○) or CD4TrVIPs (▾) (H-2b) were injected (1.5 × 106 cells/mouse) in both recipients 2 days after allogeneic transplantation, and survival was monitored (10 animals/group). *P < .01 versus untreated recipients. (B) The effect of CD4TrVIPs is dose-dependent. Balb/c mice (H-2d) received transplants of T-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from B6 (H-2b) mice and CD4TrVIPs (H-2b) were injected in recipients together with transplantation at different numbers: 1.5 × 106 cells, BMS/TrVIPs ratio of 10:1 (○); 3 × 105 cells, BMS/TrVIPs ratio 50:1 (▾); or 1.5 × 105 cells, BMS/TrVIPs ratio 100:1 (▿). Untreated control mice (•, n = 10). *P < .01 versus untreated recipients. (C) Balb/c mice that were (•) or that had received injections of CD4TrVIPs and been treated with control immunoglobulin (○), anti-IL-10 (▾), anti-TGF-β (▿), or anti-IL-10 plus anti-TGFβ (▪) antibodies after BMS B6 transplantation (n = 10). *P < .01 versus control immunoglobulin-treated CD4TrVIPs recipients. (D) Balb/c mice (H-2d) were given transplants of T cell-depleted BM cells supplemented with 1.5 × 106 spleen mononuclear cells (BMS, 1.5 × 107 cells/mouse) from B6 (H-2b) mice. Recipients were treated with medium (untreated, •), CD8Trcontrols (○) or CD8TrVIPs (▾) (5 × 106 cells) at time of allogeneic transplantation and survival was monitored (5 animals/group). *P < .01 versus untreated recipients.

Close Modal

or Create an Account

Close Modal
Close Modal